What if you could detect cancer early enough to make a difference?
The Galleri® multi-cancer early detection test detects more than 50 types of cancer, most of which lack routine screening. All through a simple blood draw.1
Learn how the Galleri test can help your patients
This form is meant for healthcare providers. If you are hoping to request the test for yourself, please visit this page instead.
Thank You
Thank you for your submission. A representative will be in touch to assist you soon.
Today, most cancers lack routine screening
The majority of cancers are found too late, when the prognosis is often poor and treatment options are limited.2
*Data estimated for 2020 among individuals 50 – 79 years old. When calculated for 2021, 68% of cancer deaths are caused by cancers without recommended screening.
Introducing the Galleri multi-cancer early detection test
The Galleri test provides
Early cancer detection
The Galleri test detects many cancers that do not have routine screening tests.1
Simple implementation
Requiring only a single blood draw, the Galleri test offers a convenient way to get screened for cancer signals.
Broad and actionable
The Galleri test detects a cancer signal across more than 50 types of cancer and predicts the origin of the cancer signal with high accuracy.1
A
Adrenal Cortical Carcinoma
Ampulla of Vater
Anus
Appendix, Carcinoma
B
Bile Ducts, Distal
Bile Ducts, Intrahepatic
Bile Ducts, Perihilar
Bladder, Urinary
Bone
Breast
C
Cervix
Colon and Rectum
E
Esophagus and Esophagogastric Junction
G
Gallbladder
Gastrointestinal Stromal Tumor
Gestational Trophoblastic Neoplasms
K
Kidney
L
Larynx
Leukemia
Liver
Lung
Lymphoma (Hodgkin and Non-Hodgkin)
M
Melanoma of the Skin
Merkel Cell Carcinoma
Mesothelioma, Malignant Pleural
N
Nasal Cavity and Paranasal Sinuses
Nasopharynx
Neuroendocrine Tumors of the Appendix
Neuroendocrine Tumors of the Colon and Rectum
Neuroendocrine Tumors of the Pancreas
O
Oral Cavity
Oropharynx (HPV-Mediated, p16+)
Oropharynx (p16-) and Hypopharynx
Ovary, Fallopian Tube and Primary Peritoneum
P
Pancreas, exocrine
Penis
Plasma Cell Myeloma and Plasma Cell Disorders
Prostate
S
Small Intestine
Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs
Soft Tissue Sarcoma of the Head and Neck
Soft Tissue Sarcoma of the Retroperitoneum
Soft Tissue Sarcoma of the Trunk and Extremities
Soft Tissue Sarcoma Unusual Histologies and Sites
Stomach
T
Testis
U
Ureter, Renal Pelvis
Uterus, Carcinoma and Carcinosarcoma
Uterus, Sarcoma
V
Vagina
Vulva
The most frequently asked questions
The Galleri test is a qualitative, next-generation sequencing-based, in vitro diagnostic test intended for the detection of DNA methylation patterns using cell-free DNA (cfDNA) isolated from human peripheral whole blood. DNA methylation is a natural process used by cells to regulate gene expression. Certain DNA methylation patterns can serve as a signal of cancer and provide information about the origin of the cancer signal.
The Galleri test detects methylation patterns of cell-free DNA (cfDNA) that could indicate the presence of cancer. When a cancer signal is detected, the test predicts the origin of the cancer signal with high accuracy. The Galleri test does not detect specific genetic mutations and does not determine an individual’s genetic risk for cancer. Learn more about the Galleri test.
The Galleri test is only commercially available in the US at this time. The Galleri test will be available to eligible patients as part of a clinical study in partnership with the United Kingdom’s National Health Service (NHS) in mid-2021. More details provided here.
The Galleri test should be used in addition to guideline-recommended cancer screening, such as mammography, colonoscopy, prostate specific antigen (PSA) or cervical cancer screening. Galleri can benefit patients with an elevated risk of cancer due to age, such as those aged 50 or older.
The list price for the Galleri test is $949. Contact your account representative or GRAIL Customer Service at 833−694−2553 or customerservice@grail.com if you have questions about pricing.
Important Safety Information
The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.
Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of “No Cancer Signal Detected” does not rule out cancer. A test result of “Cancer Signal Detected” requires confirmatory diagnostic evaluation by medically established procedures (e.g. imaging) to confirm cancer.
If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.
Laboratory / Test Information
GRAIL’s clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists (CAP). The Galleri test was developed, and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. GRAIL’s clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.
Learn how the Galleri test can help your patients
This form is meant for healthcare providers. If you are hoping to request the test for yourself, please visit this page instead.
Thank You
Thank you for your submission. A representative will be in touch to assist you soon.
- Klein E, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test. Oral presentation at: American Association for Cancer Research; April, 2021;LB013.
- Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021 Jan;71(1):7 – 33.
- Among individuals 50 – 79 years old. Assumes screening is available for all prostate, breast, cervical, and colorectal cancer cases and 33% of lung cancer cases (based on estimated proportion of lung cancers that occur in screen-eligible individuals older than 40 years).
- Data on file from Surveillance, Epidemiology, and End Results (SEER) 18 Regs Research Data, Nov 2017 Submission. Includes persons aged 50 – 79. Estimated deaths per year in 2020 from American Cancer Society Cancer Facts and Figures 2020. Available at: www.cancer.org/content/dam/cancer— org/research/cancer— facts— and— statistics/annual— cancer— facts— and— figures/2020/cancer— facts— and— figures— 2020.pdf.